Pharma Start-Ups: OK Returns
This article was originally published in Start Up
Executive Summary
While pharma start-ups aren't raising the amounts of money their IPOs were in the previous year's eight-month period, desperation has hardly set in, judging by valuations.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.